Algernon Pharmaceuticals

Algernon Pharmaceuticals

Private Company
Public Company
Subsidiary of
Clinical Trials, R&D


Algernon Pharmaceuticals is a clinical stage drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Their business model is highly capital efficient and strives to deliver maximum shareholder value.

Repurposing offers several benefits over traditional drug development including a significant reduction in investment and risk, shorter research periods and potentially longer active patent life.

- Advancing new drug treatments for billion dollar global disease markets.

- Re-purposed compounds have a much lower risk of failing in human trials as a result of safety issues.

- Conducting multiple phase II clinical trials.

- Highly capital efficient business model.

Clinical Research Programs

Algernon Pharmaceuticals is focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and COVID-19.



Preclinical studies for DMT/Stroke Program

•IP filed for new forms of DMT, dosing, formulation, method of use and combination therapy for stroke rehabilitation

•Preclinical work initiated - Charles River Labs

  • DMT synthesis - Dalton Pharma Services
  • Phase 1 - Hammersmith Medicines Services

•Phase 1 planned for Q3-2021

•Phase 2 planned for 2022


  • Dr. Rick Strassman MD
  • Dr. Dennis Choi MD, PhD

IPF / Chronic Cough / Covid-19


IPF & chronic cough Phase II Trial

•20 patient open-label IPF patients with cough

•Started May 2020

Multinational Covid-19 Phase IIb/III Trial

•150 patient open-label hospitalized confirmed COVID

•Final Data –End of March, 2021


Christopher J. Moreau, Chief Executive Officer

•President, CEO & director of a TSX:V listed R&D company in the life sciences sector for over nine years.

•Experienced with startups, licensing, mergers & acquisitions,and integration.

•Over 30 years of SNR Management experience in private/publicly traded company environments.

•Has raised over $35M from capital markets.

Dr. Christopher Bryan, PhD, VP Research and Operations

•Graduated from the University of Toronto, with a PhD in organic chemistry. 

•Has synthesized hundreds of novel small molecules as potential therapeutic agents.

•Management experience in R&D, manufacturing, sales, clinical trial, IP and regulatory affairs.

•Has extensive experience in scientific writing, data analysis and literature review. 

Dr. Ahmad Khalil, MD, PhD, Chief Medical Officer

•Extensive biopharmaceutical experience bringing drugs into clinical trials over the past 20 years, acting in the capacities of Medical Director, Medical Monitor, and Clinical Consultant for a variety of companies.

•Managed multiple North American and multi-national clinical trials and clinical programs, from Phase I – IV

•Member of the Harvard Medical School Postgraduate Association, the Canadian Medical Association, the University of Montreal General Professor Syndicate, and the American Heart Association Professional Membership & Cardiovascular Sciences Councils.